- Home
- SNY vs KZR Comparison
SNY vs KZR Comparison
Compare SNY & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- KZR
- Stock Information
- Founded
- SNY 1994
- KZR 2015
- Country
- SNY France
- KZR United States
- Employees
- SNY N/A
- KZR N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- SNY Health Care
- KZR Health Care
- Exchange
- SNY Nasdaq
- KZR Nasdaq
- Market Cap
- SNY 116.5B
- KZR N/A
- IPO Year
- SNY N/A
- KZR 2018
- Fundamental
- Price
- SNY $48.12
- KZR $4.62
- Analyst Decision
- SNY Buy
- KZR Hold
- Analyst Count
- SNY 2
- KZR 2
- Target Price
- SNY $62.50
- KZR $9.00
- AVG Volume (30 Days)
- SNY 2.1M
- KZR 39.8K
- Earning Date
- SNY 07-24-2025
- KZR 08-12-2025
- Dividend Yield
- SNY 3.31%
- KZR N/A
- EPS Growth
- SNY 39.56
- KZR N/A
- EPS
- SNY 5.45
- KZR N/A
- Revenue
- SNY $48,817,552,946.00
- KZR N/A
- Revenue This Year
- SNY $3.39
- KZR N/A
- Revenue Next Year
- SNY $7.05
- KZR N/A
- P/E Ratio
- SNY $8.86
- KZR N/A
- Revenue Growth
- SNY N/A
- KZR N/A
- 52 Week Low
- SNY $45.80
- KZR $3.62
- 52 Week High
- SNY $60.12
- KZR $9.18
- Technical
- Relative Strength Index (RSI)
- SNY 41.60
- KZR 55.92
- Support Level
- SNY $47.56
- KZR $4.07
- Resistance Level
- SNY $48.93
- KZR $4.74
- Average True Range (ATR)
- SNY 0.64
- KZR 0.35
- MACD
- SNY -0.06
- KZR 0.00
- Stochastic Oscillator
- SNY 26.24
- KZR 62.00
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.